B.Riley Financial analyst Marc Wiesenberger maintained a Buy rating on BioLife Solutions (NASDAQ:) on Friday, setting a price target of $60, which is approximately 101.75% above the present share price of $29.74.
Wiesenberger expects BioLife Solutions to post earnings per share (EPS) of -$0.06 for the second quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in BioLife Solutions, with an average price target of $56.
The analysts price targets range from a high of $60 to a low of $50.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $14.73 million and a net profit of -$1.39 million. The company’s market cap is $1.2 billion.
According to TipRanks.com, B.Riley Financial analyst Marc Wiesenberger is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 43.7% and a 64.13% success rate.
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.